In re Chapman
In re...(U.S. Fed. Cir., Drugs & Biotech, Health Law, Intellectual Property, Patent) Decision of the US Patent and Trademark Office, Board of Patent Appeals and Inferences, finding that certain claims of an application directed at technology involving divalent antibody fragments were unpatentable as obvious, is vacated and remanded as the Board’s opinion includes erroneous statements that are not harmless because they increase the likelihood that plaintiff was erroneously denied a patent on grounds of obviousness.
